Source: China News Service, China News Service
On May 1, the clinical study of the inactivated vaccine of the New Coronavirus variant developed by Sinopharm China Biological Institute of Beijing Biological Products was officially launched in Hangzhou, and the first dose of vaccination was completed on the same day. This is the world's first inactivated covid-19 vaccine to enter clinical trials against the Ami kerong variant.
Li Lanjuan, an academician of the Chinese Academy of Engineering, said in an interview that the current Opmi kerong virus still seriously threatens the health of personnel, and the research and development of related vaccines is of great significance.
Academician of the Chinese Academy of Engineering Li Lanjuan:
The development of vaccines for the Omilon variant is very important, of course, the original vaccine is still effective, but after the development of the vaccine for the variant, it is possible to have a better immune effect. This also proves the speed of China's fight against the epidemic and The efficiency of China. We believe that through rigorous clinical research, the safety and efficacy of the vaccine are further demonstrated to ensure the application of future vaccines.
On May 1, Li Lanjuan (center), an academician of the Chinese Academy of Engineering, introduced the clinical research of the inactivated vaccine of the New Coronavirus variant of the Ami Kerong strain. China News Service reporter Zhang Yuhuan photographed
The new vaccine that has entered the clinical research stage, how the clinical effect is, and whether those who have been vaccinated with the new crown vaccine can continue to be vaccinated, Li Lanjuan said that it is necessary to further explore and verify the clinical response in stages.
Academician of the Chinese Academy of Engineering Li Lanjuan:
It should be said that of course, people who have not been vaccinated can be beaten, and the next step is to do clinical trials for people who have already been vaccinated, (to verify) whether it will be more effective. Because he has been vaccinated, he may already have antibodies, so it is necessary to apply to people who have not been vaccinated, nor have they been infected with the new crown, to prove the immunogenicity and comprehensive antibodies produced by him after the (newly developed) vaccine is beaten, to prove the effectiveness of the (new vaccine). At the same time, further observations of the clinical response (of the new vaccine) to prove the safety of the (new vaccine).
On May 1, medical staff made preparations for the injection. China News Service reporter Zhang Yuhuan photographed
Clinical trial vaccination volunteers said that they just saw the recruitment activities, they have not been vaccinated against the new crown, one is to strengthen their immunity, and then they can make a contribution to society. It feels good at the moment.
On May 1, healthcare workers received inactivated vaccine against the New Coronavirus variant of the Semickon variant. China News Service reporter Zhang Yuhuan photographed
Li Lanjuan introduced that the vaccine research and development for the Aomi Kerong variant was launched on December 9, 2021, and received clinical trial approval from the State Food and Drug Administration on April 26, 2022. This clinical study will contribute to the prevention and control of the novel coronavirus pneumonia epidemic.
Previously, in response to the vaccine research and development of the Aomi Kerong variant, Zheng Zhongwei, head of the vaccine research and development special class of the scientific research group and director of the Science and Technology Development Center of the National Health Commission of China, said that from the beginning of the emergence of the Aomi Kerong variant, the Chinese vaccine research and development team has taken action. "The basic principle we follow is 'I'd rather have it than use it, and we would never use it without using it.'"